D-1131-2018 Class II Terminated

Recalled by AVKARE Inc. — Pulaski, TN

FDA drug recall D-1131-2018 was initiated by AVKARE Inc. on Aug 14, 2018 and is designated Class II. Reason for recall: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. The recall status is terminated (terminated May 7, 2020). Affected quantity: 728 cartons (36,400 tablets).

Recall details

Product Type
Drugs
Report Date
Sep 5, 2018
Initiation Date
Aug 14, 2018
Termination Date
May 7, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
728 cartons (36,400 tablets)

Product description

Valsartan Tablets, USP 80 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-784-15 Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Reason for recall

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Distribution pattern

U.S. Nationwide

Code information

Lots: 18492 Exp. 11/2018; 20169 Exp. 05/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1131-2018
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1131-2018. Report a data issue: hello@regdatalab.com.